Free Trial
NASDAQ:RIGL

Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

$10.59
+0.61 (+6.11%)
(As of 07/15/2024 ET)
Today's Range
$10.01
$10.67
50-Day Range
$7.73
$11.90
52-Week Range
$7.12
$17.30
Volume
105,844 shs
Average Volume
160,214 shs
Market Capitalization
$185.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.13

Rigel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
448.9% Upside
$58.13 Price Target
Short Interest
Healthy
3.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Rigel Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.33) to $0.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

348th out of 912 stocks

Pharmaceutical Preparations Industry

160th out of 434 stocks

RIGL stock logo

About Rigel Pharmaceuticals Stock (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

RIGL Stock Price History

RIGL Stock News Headlines

The attacks will come for me after releasing this…
In my new exposé, I pull back the curtain on what’s really going on in America, what’s coming next, and what you must do to protect your assets before it’s too late.
Rigel Announces Reverse Stock Split
The attacks will come for me after releasing this…
In my new exposé, I pull back the curtain on what’s really going on in America, what’s coming next, and what you must do to protect your assets before it’s too late.
See More Headlines
Receive RIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
7/15/2024
Next Earnings (Estimated)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RIGL
CUSIP
76655960
Employees
160
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$58.13
High Stock Price Target
$150.00
Low Stock Price Target
$12.50
Potential Upside/Downside
+449.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-25,090,000.00
Pretax Margin
-16.45%

Debt

Sales & Book Value

Annual Sales
$116.88 million
Book Value
($1.64) per share

Miscellaneous

Free Float
15,971,000
Market Cap
$185.78 million
Optionable
Optionable
Beta
0.96

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Raul R. Rodriguez (Age 63)
    President, CEO & Director
    Comp: $1.17M
  • Mr. Dean L. Schorno CPA (Age 61)
    Executive VP & CFO
    Comp: $736.72k
  • Mr. Raymond J. Furey J.D. (Age 56)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $683k
  • Mr. David A. Santos (Age 61)
    Executive VP & Chief Commercial Officer
    Comp: $737.18k
  • Ms. Julie Patel
    Senior VP of Human Resources
  • Dr. Esteban S. Masuda (Age 62)
    Executive Vice President of Research
    Comp: $537.21k
  • Mr. Joseph Lasaga (Age 49)
    Executive VP & Chief Business Officer
  • Dr. Lisa Rojkjaer M.D. (Age 58)
    Executive VP & Chief Medical Officer
  • Mr. Tarek Sallam
    Vice President of Marketing

RIGL Stock Analysis - Frequently Asked Questions

How have RIGL shares performed this year?

Rigel Pharmaceuticals' stock was trading at $14.50 at the start of the year. Since then, RIGL shares have decreased by 27.0% and is now trading at $10.59.
View the best growth stocks for 2024 here
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.20. The biotechnology company had revenue of $29.53 million for the quarter, compared to the consensus estimate of $31.28 million.

When did Rigel Pharmaceuticals' stock split?

Rigel Pharmaceuticals shares reverse split on Thursday, June 27th 2024. The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among the company's employees.

Who are Rigel Pharmaceuticals' major shareholders?

Top institutional shareholders of Rigel Pharmaceuticals include SG Americas Securities LLC (0.09%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno and David A Santos.
View institutional ownership trends
.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB) and Novan (NOVN).

This page (NASDAQ:RIGL) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners